论文部分内容阅读
1963年首先报告抗磺胺嘧啶的脑膜炎球菌的出现和传播,从此结束了已使用20年的磺胺嘧啶预防法。通过6年的研究,研制了纯化夹膜多糖菌苗,以后证明这些菌苗预防血清型C群和A群菌病有效。近年美国脑膜炎球菌病已处于低潮,但巴西则相当流行。1971年以来,圣保罗流行抗磺胺嘧啶的血清型C群菌病,每年总发病率为11.3/10万人,约10倍于美国。1974年第2季度初,脑膜炎球菌出现突变菌株,在7、8月份每月发病率约为65/10万人(共13,000多例),80％为血清型A群菌株,多数菌株抗磺胺嘧啶。目前正使用纯化夹膜多糖菌苗(A和C群)进行大规模的免疫预防。
The first reported in 1963 the emergence and spread of anti-sulfadiazine meningococci, from the end of the sulfadiazine preventive method that has been used for 20 years. After 6 years of research, the purified jacca polysaccharide vaccine was developed and proved to be effective in preventing serogroup C and group A bacteriosis. In recent years, the meningococcal disease in the United States has been at a low ebb, but Brazil is quite prevalent. Since 1971, the prevalence of sulfadiazine serogroup C group disease in Sao Paulo has a total annual incidence rate of 11.3 / 10 million, about 10 times that of the United States. At the beginning of the second quarter of 1974, meningococcal strains were mutated, with a monthly incidence rate of 65/10 million (more than 13,000 cases) in July and August and 80% serogroup A strains. Most strains were resistant to sulfa Pyrimidine. Purified jacca polysaccharide vaccines (groups A and C) are currently being used for large-scale immunoprophylaxis.